Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
595results about "Transferrins" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Methods and materials for making and using transgenic dicamba-degrading organisms
Owner:BOARD OF RGT UNIV OF NEBRASKA
Sclerostin-binding antibody
Owner:UCB SA +1
Megalin-based delivery of therapeutic compounds to the brain and other tissues
InactiveUS20050042227A1Easy to transportImprove propertiesBiocideNervous disorderBlood–brain barrierDrug delivery
Owner:HORIZON ORPHAN LLC
Modified transferrin fusion proteins
InactiveUS7176278B2Increased serum half-lifeImprove bioavailabilityAntibody mimetics/scaffoldsVirus peptidesDiseaseSerum ige
The present invention discloses fusion proteins comprising transferrin, lactoferrin or melanotransferrin fused to glucagon-like peptide 1 (GLP-1). In one embodiment of the invention, the fusion protein displays increased serum half-life as compared to a GLP-1 peptide in an unfused state. The invention includes a pharmaceutical composition comprising the GLP-1 fusion protein of the invention and a carrier. The fusion protein of the invention can be administered to a subject for treatment of diseases or conditions treatable by GLP-1, including, but not limited to, diabetes, obesity, congestive heart failure and inflammatory bowel syndrome.
Owner:BIOREXIS TECH INC
Conjugation methods
ActiveUS20110003969A1Reduce potential steric hindrancePeptide/protein ingredientsMammal material medical ingredientsBiochemistryAntibody
This invention describes a method of conjugating a cell binding agent such as an antibody with an effector group (e.g., a cytotoxic agent) or a reporter group (e.g., a radionuclide), whereby the reporter or effector group is first reacted with a bifunctional linker and the mixture is then used without purification for the conjugation reaction with the cell binding agent. The method described in this invention is advantageous for preparation of stably-linked conjugates of cell binding agents, such as antibodies with effector or reporter groups. This conjugation method provides in high yields conjugates of high purity and homogeneity that are without inter-chain cross-linking and inactivated linker residues
Owner:IMMUNOGEN INC
Methods and compositions for treatment of symptoms associated with intracranial hemorrhage
ActiveUS10442852B2Good treatment effectAvoid symptomsPeptide/protein ingredientsTransferrinsMedicineFc domain
Methods and compositions are provided for the treatment of a patient with intracranial hemorrhage (ICH). Methods include the use of the products of recombinant constructs such as those that contain lactoferrin, as well as fusion protein constructs of lactoferrin and Fc domain for IgG.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Antimicrobial compositions and methods
InactiveUS20050053593A1Easy to handleReduce Microbial ContaminationAntibacterial agentsBiocideLipid formationAlcohol sugars
The present invention is generally related to a product and process to reduce the microbial contamination on organic matter, such as processed meat, fruits and vegetables, plant parts, inanimate surfaces such as textiles and stainless steel, and in the mouth or on dental products. In particular, the invention is related to a product and process to disinfect surfaces using an antimicrobial composition containing an antimicrobial lipid, an enhancer selected from the group consisting of bacteriocins, antimicrobial enzymes, sugars, sugar alcohols, iron-binding proteins and derivatives thereof, siderophores, and combinations thereof, and optionally a surfactant.
Owner:3M INNOVATIVE PROPERTIES CO
Antineoplastic conjugates of transferrin, albumin and polyethylene glycol
Conjugates of transferrin, albumin and polyethylence glycol consisting of native or thiolated transferrin or albumin or of polyethylene glycol (MW between approximately 5,000 and 20,0000) with at least one HS-, HO- or H2N group and cytostatic compounds derived through maleinimide or N-hydroxysuccinimide ester compounds, such as doxorubicin, daunorubicin, epirubicin, idarubicin, mitoxandrone, chloroambucil, melphalan, 5-fluorouracyl, 5'-desoxy-5-fluorouridine, thioguanine, methotrexate, paclitaxel, docetaxel, topotecan, 9-aminocamptothecin, etoposide, teniposide, mitopodoside, vinblastine, vincristine, vindesine, vinorelbine or a compound of general formula A, B, C or D, where n=0-6, X=-NH2, -OH, -COOH, -O-CO-R-COR*, -NH-CO-R-COR*, where R is an aliphatic carbon chain with 1-6 carbon atoms or a substituted or unsubstituted phenylene group and R* H, phenyl, alkyl with 1-6 carbon atoms.
Owner:KRATZ FELIX
Expression of processed recombinant lactoferrin and lactoferrin polypeptide fragments from a fusion product in Aspergillus
The subject invention provides for the production of lactoferrins and lactoferrin polypeptide fragments using the host cells Aspergillus in combination with novel plasmid constructs. More specifically, the subject invention provides novel vector constructs capable of producing lactoferrins and lactoferrin polypeptide fragments in Aspergillus host cells. More particularly, the subject invention provides for novel plasmid constructs suitable for use with Aspergillus and especially Aspergillus awamori, niger and oryzae host cells, which enables them to produce large amounts of recombinant lactoferrins and lactoferrin polypeptide fragments.
Owner:AGENNIX
Medicaments for healing skin conditions in humans
InactiveUS20040214750A1Short timeQuick cureBiocideCosmetic preparationsOral medicationAdditive ingredient
The present invention is directed to a novel progression of topical and oral administration or use of lactoferrin or lactoferrin and other biological ingredients to prevent and treat dermatological conditions or disorders in humans. More specifically, the present invention is directed to the administration of lactoferrin in a topical material such as an ointment or cream to the skin of humans and also including a oral administration, together the topical and oral administration has a synergetic effect in the treatment of the skin. The progression of medicaments of the present invention are: 1) lactoferrin; 2) lactoferrin and conjugated linoleic acids; 3) lactoferrin, a plant or animal derived lipid and oblepicha; 4) lactoferrin, a plant or animal derived lipid, oblepicha, and an omega fatty acid; and 5) lactoferrin, a plant or animal derived lipid, oblepicha, an omega fatty acid and a whey protein.
Owner:GEORGIADES IZOLDA M
Compositions for treating biofilm
Owner:ALLOTROPE PHARMA INC
Affinity based system for detecting particulates in a fluid
InactiveUS20060194264A1Bioreactor/fermenter combinationsHeating or cooling apparatusParticulatesMicroparticle
This invention provides methods and apparatus for detecting and quantifying particulate matter suspended in a fluid. Specifically, the invention provides an integrated, affinity-binding based, analytical system comprising a platform for performing an affinity-binding based assay for specifically binding particulates including microbial cells, and a detection means for detecting the particulates specifically bound to a defined surface or chamber comprising the platform. Methods for using the analytical systems of the invention are also provided.
Owner:TECAN TRADING AG
Treatments for contaminant reduction in lactoferrin preparations and lactoferrin containing compositions
A method of preparing an ultra-cleansed lactoferrin preparation, termed treatment for contaminant reduction (TCR) is provided which includes the steps of treating commercial lactoferrin preparation with at least one each of surfactants, antioxidants and polyphenols to form purified lactoferrin (LF-TCR) and drying the LF-TCR. Additionally a therapeutic lactoferrin composition is provided which contains LF-TCR and optionally surfactants, antioxidants, polyphenols, tissue / membrane diffusion facilitating agents and anionic compounds. The therapeutic lactoferrin composition can additionally contain bioactive agents, dietary supplements, nutraceuticals / functional foods, prophylactic agents, therapeutic agents and probiotic lactic acid bacteria.
Owner:NAIDU LP
Methods for regulating inflammatory mediators and peptides useful therein
The present invention includes methods of modulating cellular secretory processes. More specifically the present invention relates to modulating or reducing the release of inflammatory mediators from inflammatory cells by inhibiting the mechanism associated with the release of inflammatory mediators from the vesicles or granules in the inflammatory cells. In this regard, the present invention discloses an intracellular signaling mechanism that illustrates several novel intracellular targets for pharmacological intervention in disorders involving secretion of inflammatory mediators from vesicles in inflammatory cells. MANS peptide and active fragments thereof are useful in such methods.
Owner:BIOMARK PHARMACEUTICALS LTD +1
Targeted therapeutics based on engineered proteins that bind EGFR
ActiveUS8524244B2Improves one or more pharmacokinetic properties of the polypeptidesIncreased serum half-lifePeptide/protein ingredientsAntibody mimetics/scaffoldsNucleotideADAMTS Proteins
Owner:BRISTOL MYERS SQUIBB CO
Carbohydrate oxidase and use thereof in baking
The properties of dough or bread can be improved by the addition of a carbohydrate oxidase which can oxidize the reducing end of an oligosaccharide more efficiently than the corresponding monosaccharide, e.g., preferentially oxidizing maltodextrins or cellodextrins over glucose. A novel carbohydrate oxidase having the capability to oxidize maltodextrins and cellodextrins more efficiently than glucose may be obtained from a strain of Microdochium, particularly M. nivale. The amino acid sequence of the novel carbohydrate oxidase has very low homology (<20% identity) with known amino acid sequences.
Owner:NOVOZYMES AS
P97-antibody conjugates and methods of use
The present invention provides p97-antibody conjugates and related compositions and methods, which may be used in any of a variety of therapeutic methods, including methods for the treatment of cancers such as Her2 / neu-expressing and Her1 / EGFR-expressing cancers.
Owner:BIOASIS TECH
Modified transferrin fusion proteins
InactiveUS20060205037A1Reduced glucose levelIncrease satietyPeptide/protein ingredientsAntibody mimetics/scaffoldsHalf-lifeTransferrin
Modified fusion proteins of a transferrini moiety, a GLP-1 moiety and a linker moiety, with increased productivity, bioactivity and serum half-life are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation. The fusion proteins of the invention are useful for the treatment of Type 2 diabetes, Type 1 diabetes, obesity, congestive heart failure, and non-fatty liver disease.
Owner:BIOREXIS PHARMA CORP
Methods and Systems for Protein and Peptide Evidence Assembly
InactiveUS20090053819A1Reduce manual inspectionTransferrinsAlbumin peptidesProtein insertionMass Spectrometry-Mass Spectrometry
The present teachings provide methods and systems for the identification of proteins via peptide analysis. Some embodiments analyze proteins identified by analysis techniques such as mass spectrometry and build protein groups out of results. Groups can be formed by collecting like proteins and examining the group so as to identify if it is likely that only one form of a protein is present or, if there is enough evidence to support the presence of alternate forms. Various embodiments provide visual reports that can be interactive. These reports can allow a user to visualize relationships between proteins both intra- and inter-group. Methods are also introduced that can reduce the identification of false positives by taking into account a priori information.
Owner:APPL BIOSYSTEMS INC
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
InactiveUS20120190051A1Eliminate needPeptide/protein ingredientsTransferrinsErythropoietin receptorFactor VIII vWF
Disclosed are methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, disclosed are assays that detect one or more markers selected from the group consisting of Prostatic acid phosphatase, Lactotransfenin, Soluble erythropoietin receptor, Von Willebrand factor, Soluble endothelial protein C receptor, and Beta-2-glycoprotein 1 as diagnostic and prognostic biomarkers in renal injuries.
Owner:ASTUTE MEDICAL
Molecular conjugates for use in treatment of cancer
InactiveUS7153946B2Reduce and eliminate side effectEfficient ConcentrationBiocideSugar derivativesMoietyOncology
A molecular conjugate is provided having the formula:wherein R1 is a de-hydroxyl or de-amino moiety respectively of a hydroxyl-bearing or amino-bearing biologically active molecule or an analog or derivative thereof, and Z is —O— or —NH—, respectively, Y is a straight or branched alkyl having 1 to 20 carbons that may be optionally substituted with one or more phenyl, a cycloalkyl optionally substituted with one or more alkyl or phenyl, or an aromatic group optionally substituted with one or more alkyl groups, electron-withdrawing groups, or electron-donating groups; and R2 is —CH═CH(W), —CH(OH)CH(OH)W, or —C(O)H, where W can be H, a straight or branched alkyl having 1 to 20 carbons that may be optionally substituted with one or more phenyl, a cycloalkyl optionally substituted with one or more alkyl or phenyl, or an aromatic group optionally substituted with one or more alkyl groups, electron-withdrawing groups, or electron-donating groups.
Owner:TAPESTRY PHARMACEUTICALS INC
Metallo-protein and tocotrienol (mp-t3) compositions and uses thereof
Metallo-proteins including but not limited to lactoferrin (LF), transferrin (TF) and ovotransferrin (OTF) (all members of transferrin family), ceruloplasmin (CP) and metallo-thionein (MT) were found to stabilize and enhance the bio-functional activity of tocotrienol (T3), T3 mixtures or derivates. The synergism between MP and T3 also promote the intestinal transfer and the ultimate bio-availability of T3 and T3-derivatives for physiological functions. Such functional synergism includes hypocholesterolemic, anti-thrombotic, antioxidant, anti-athermogenic, anti-inflammatory and immuno-regulatory activities of T3 agents. These T3 compositions are useful as pharmaceuticals, in cosmetics, in foods and as nutritional supplements.
Owner:NAIDU LP
Method for improving stool characteristics in infants
In accordance with the present invention, a novel method for improving the stool characteristics, reducing the incidence of diarrhea, and firming the stool of a formula-fed infant of a formula-fed infant has been discovered. The method comprises administering to the infant at least one prebiotic and hydrolyzed pectin.
Owner:MEAD JOHNSON NUTRITION
Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects
InactiveUS20050075277A1Reduce infectionReduce inflammationOrganic active ingredientsBiocidePharmaceutical formulationLactoferrin
The present invention relates to a use of lactoferrin in prophylaxis against infection and / or inflammation in immunosuppressed subjects or subjects whose immune systems are expected to be suppressed. Specifically, the invention provides a method of preventing infection and / or inflammation in individuals by administrating an effective amount of pharmaceutical formulation comprised of a lactoferrin product.
Owner:AGENNIX
Ultrapure transferrin for pharmaceutical compositions
The present invention relates to an ultrapure human transferrin, and to methods for manufacturing the ultrapure transferrin. The transferrin may be holo-, apo- or at any desired degree of iron saturation. The invention further relates to the use of ultrapure transferrin as the protein moiety of conjugates, and to pharmaceutical compositions comprising ultra transferrin alone as well as in the form of a conjugate.
Owner:KAMADA
Chromophore Probes for Optical Imaging
Chromophore probes that are capable of being taken up by, retained by or bound to a biocompatible molecule to form an imaging construct are provided. Various activation strategies of the resulting imaging construct are also provided.
Owner:VISEN MEDICAL INC
Treatments for contaminant reduction in lactoferrin preparations and lactoferrin containing compositions
A method of preparing an ultra-cleansed lactoferrin preparation, termed treatment for contaminant reduction (TCR) is provided which includes the steps of treating commercial lactoferrin preparation with at least one each of surfactants, antioxidants and polyphenols to form purified lactoferrin (LF-TCR) and drying the LF-TCR. Additionally a therapeutic lactoferrin composition is provided which contains LF-TCR and optionally surfactants, antioxidants, polyphenols, tissue / membrane diffusion facilitating agents and anionic compounds. The therapeutic lactoferrin composition can additionally contain bioactive agents, dietary supplements, nutraceuticals / functional foods, prophylactic agents, therapeutic agents and probiotic lactic acid bacteria.
Owner:NAIDU LP
Expression of human milk proteins in transgenic plants
Owner:INVITRIA INC
Targeted therapeutics based on engineered proteins that bind EGFR
ActiveUS20110053842A1Improves one or more pharmacokinetic properties of the polypeptidesIncreased serum half-lifePeptide/protein ingredientsAntibody mimetics/scaffoldsNucleotideADAMTS Proteins
The present invention relates to single domain proteins that bind to epidermal growth factor receptor (EGFR). The invention also relates to single domain proteins for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
Owner:BRISTOL MYERS SQUIBB CO
Prostaglandin f2alpha analogs and their use in combination with antimicrobial proteins for the treatment of glaucoma and intraocular hypertension
InactiveUS20060264353A1High indexReduce morbidityAntibacterial agentsBiocideProstaglandin analogPreservative
An ophthalmic formulation for the treatment of glaucoma and intraocular pressure with a prostaglandin compound of the F-series (PGF), and particularly a prodrug form of a PGF2α analog, such as an ester, amide, or internal lactone, wherein preservative is an antimicrobial peptide, such as lactoferrin. In particularly preferred embodiments, the prostaglandin compound is a macrocyclic internal 1,15-lactone, such as the 16-aryloxy prostaglandin analogs, illustratively fluprostenol or cloprstenol.
Owner:CAYMAN CHEMICAL COMPANY
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com